Cancer Treatment Results  Survival Rates Cancer Treatments / Therapy Results

Click here to go back to your search results.

Rectal Cancer treatment details. Chemotherapy. Surgery. The University of Texas, MD Anderson Cancer Center, Houston, Texas, United States

Survival: 9.0 months
Toxicity Grade: 4
Treatments: Chemotherapy
Country: United States
City/State/Province: Houston, Texas
Hospital: The University of Texas, MD Anderson Cancer Center
Journal: Link
Date: 1/2004

Patients: This Phase II study involved 15 evaluable patients with metastatic colorectal cancer (adenocarcinoma).

Treatment: The treatment consisted of the chemotherapy drug exatecan mesylate (DX-8951f) after surgery.

Toxicity: The principal toxicity was neutropenia, with grade 3 and 4 toxicities in three and eight patients, respectively. Non-hematologic toxicities included: fatigue (grade 1-3), nausea (grade 1-2), diarrhea (grade 1-2), abdominal pain (grade 1-3), and fever (grade 1-3).

Results: Median survival time was 9.0 months. The authors concluded that DX-8951f at this dose and schedule had no significant activity in this patient population.

Support: One of the study’s authors is associated with Daiichi Pharmaceutical Corp., the company that manufactures exatecan mesylate (DX-8951f).

Correspondence: Melanie Royce, MD

E-mail to a Friend Email Physician More Information